Biogen BIIB Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $1.34B-17.8% | $1.63B+40.5% | $1.16B-60.8% | $2.96B+69.4% | ||
| $779.9M+15.8% | $673.2M+36.1% | $494.8M-4.6% | $518.4M+6.3% | ||
| $290.8M-0.1% | $291.2M+10.2% | $264.2M+4.0% | $254.1M+6.5% | ||
| $361.6M+329% | -$158.1M— | —— | -$168.6M— | ||
| -$102.7M+53.8% | -$222.3M— | —— | $223.6M— | ||
| $64.7M-76.4% | $273.8M— | —— | $338.3M-26.8% | ||
| $171.1M— | —— | —— | -$113.4M— | ||
| -$248M-38.8% | -$178.7M-142% | -$73.9M+19.7% | -$92M+36.3% | ||
| —— | —— | —— | —— | ||
| -$958.1M-1,321% | $78.5M+126% | -$299M-110% | -$142.3M— | ||
| —— | —— | -$277.1M— | —— | ||
| —— | —— | —— | —— | ||
| $2.2B-23.3% | $2.88B+85.9% | $1.55B— | —— | ||
| $153.8M+0.1% | $153.7M-44.5% | $277M+15.3% | $240.3M-6.9% | ||
| —— | $0-100% | $5.14B+49.1% | $3.45B-9.5% | ||
| —— | $0-100% | $7.38B+101% | $3.67B-31.3% | ||
| $31.6M-84.7% | $206.1M+499% | $34.4M+1,086% | $2.9M-84.6% | ||
| -$42.9M-1,013% | $4.7M-58.4% | $11.3M+146% | -$24.6M— | ||
| —— | $0— | $0— | $0-100% | ||
| -$1.37B-71.6% | -$799.2M+80.5% | -$4.1B-339% | $1.72B+405% | ||
| —— | —— | —— | —— | ||
| $281.2M— | $0— | $0+100% | -$5.6M+75.5% | ||
| -$301.9M+56.3% | -$691.4M— | —— | -$1.75B+16.6% | ||
| $105.1M+255% | -$67.7M— | —— | —— | ||
| —— | —— | -$2.4B— | —— | ||
| $240.8M+4.7% | $230M+630% | $31.5M— | $0— | ||
| —— | —— | —— | —— | ||
| $29.6M-71.0% | $101.9M-18.1% | $124.4M-63.0% | $336.2M+96.4% | ||
| $52.9M— | $0— | $0— | —— | ||
| -$68.3M+57.2% | -$159.6M-7.7% | -$148.2M+28.8% | -$208.2M-3.0% | ||
| $85M— | $0— | $0— | —— | ||
| -$42.9M-1,013% | $4.7M-58.4% | $11.3M+146% | -$24.6M— | ||
| —— | $0— | $0— | —— | ||
| $31.6M-84.7% | $206.1M+499% | $34.4M+1,086% | $2.9M-84.6% | ||
| $0-100% | $406.8M-48.4% | $788.1M-20.4% | $990.3M— | ||
| —— | —— | -$6M-7.1% | -$5.6M+75.5% | ||
| $2.05B-24.7% | $2.72B+106% | $1.32B— | —— | ||
| $2.05B-24.7% | $2.72B+106% | $1.32B— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Biogen generate?
- Biogen (BIIB) generated $2.6B in operating cash flow over the trailing twelve months.
- What is Biogen's free cash flow?
- After $167.9M of capital expenditures, Biogen's free cash flow was $2.4B over the trailing twelve months, down 0.6% year over year.
- Where does Biogen's cash flow data come from?
- Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
